ArticleBMC pediatrics2025
"Single surgeon" and "single site" total thoracoscopic surgery for paediatric extralobular pulmonary sequestration.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Staged uniportal video-assisted thoracoscopic bilateral lower lobectomy for bilateral intralobar pulmonary sequestration complicated byFrontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo compare the clinical outcomes of "Single Surgeon" and "Single Site" total thoracoscopic surgery with multi-portal video-assisted thoracic surgery (M-VATS) in the treatment of paediatric extralobar sequestration (ELS), and to evaluate its safety and feasibility in routine practice.
methodsWe retrospectively analysed 51 paediatric ELS cases treated thoracoscopically at our institution from January 2020 to March 2025. Patients were grouped by surgical approach: 18 underwent single-site thoracoscopy, and 33 underwent M-VATS. Clinical parameters were compared between groups.
resultsCompared to M-VATS, the single-site group showed significantly reduced operative time (P = 0.02), blood loss (P < 0.01), hospital stay (P < 0.01), and expenses (P < 0.01). No bronchopleural fistulas, postoperative pneumonia, or conversions to open surgery occurred in either group.
conclusions"Single Surgeon" and "Single Site" thoracoscopic surgery offers distinct advantages, including minimized incisions, faster recovery, and reduced resource consumption, aligning with modern minimally invasive and enhanced recovery practices. The technique demonstrates safety, efficiency, and cost-effectiveness, supporting its broader clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.